|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400084418 |
|
最近更新日期: Date of Last Refreshed on: |
2024-05-16 10:50:19 |
|
注册时间: Date of Registration: |
2024-05-16 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
智能髋、踝联动动力外甲的研发及其在获得性脑损伤康复中的应用 |
|
Public title: |
The development of intelligent hip-ankle linkage powered exoskeleton and its application for rehabilitation in hemiplegic patients with acquired brain injury |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
智能髋、踝联动动力外甲的研发及其在获得性脑损伤康复中的应用 |
|
Scientific title: |
The development of intelligent hip-ankle linkage powered exoskeleton and its application for rehabilitation in hemiplegic patients with acquired brain injury |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
康晓宇 |
研究负责人: |
刘丽旭 |
|
Applicant: |
Xiaoyu Kang |
Study leader: |
Lixu Liu |
|
申请注册联系人电话: Applicant telephone: |
+86 131 6752 7699 |
研究负责人电话: Study leader's telephone: |
+86 136 7126 2202 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
kangxy0509@126.com |
研究负责人电子邮件: Study leader's E-mail: |
liulixu2004@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市丰台区角门北路10号 |
研究负责人通讯地址: |
北京市丰台区角门北路10号 |
|
Applicant address: |
10 Jiaomen Road North, Fengtai District, Beijing, China |
Study leader's address: |
10 Jiaomen Road North, Fengtai District, Beijing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
北京博爱医院 |
||
|
Applicant's institution: |
Beijing Bo'ai Hospital |
||
|
研究负责人所在单位: |
北京博爱医院 |
||
|
Affiliation of the Leader: |
Beijing Bo'ai Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024-015-1 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国康复研究中心医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of China Rehabilitation Research Center |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-03-13 00:00:00 |
||
|
伦理委员会联系人: |
孟丽君 |
||
|
Contact Name of the ethic committee: |
Lijun Meng |
||
|
伦理委员会联系地址: |
北京市丰台区角门北路18号 |
||
|
Contact Address of the ethic committee: |
18 Jiaomen Road North, Fengtai District, Beijing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 8702 0512 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
北京博爱医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Beijing Bo'ai Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市丰台区角门北路10号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
10 Jiaomen Road North, Fengtai District, Beijing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
首都卫生发展科研专项 |
||||||||||||||||||||||
|
Source(s) of funding: |
Capital’s Funds for Health Improvement and Research |
||||||||||||||||||||||
|
Target disease: |
Stroke or traumatic brain injury |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究拟研发智能髋、踝关节联动动力外甲并应用于获得性脑损伤偏瘫患者,评估其安全性和适配度。采用单中心、前瞻性、随机对照研究,探讨智能髋、踝联动动力外甲对脑损伤后偏瘫患者下肢运动功能和步行能力的康复疗效,同时结合fMRI研究脑功能重塑机制,希望为脑损伤患者提供一种安全便捷、低成本、高效益的新的康复治疗手段,以提高患者的步行能力和ADL能力,减轻家庭和社会的负担。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study intends to develop and apply intelligent hip-ankle linkage powered exoskeleton to hemiplegic patients with acquired brain injury, and evaluate its safety and fitness. A single-center, prospective, randomized controlled study was conducted to explore the effects of intelligent hip-ankle linkage powered exoskeleton on lower limb motor function and walking ability of hemiplegic patients with brain injury. Meanwhile, fMRI was combined to study the mechanism of brain function remodeling, hoping to provide a safe, convenient, low-cost and cost-effective new rehabilitation treatment for patients with brain injury in order to improve the walking ability and ADL ability of patients, reduce the burden of family and society. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①卒中或脑外伤患者:缺血性或出血性卒中诊断标准符合“中国各类主要脑血管病诊断要点 2019”卒中诊断标准;脑外伤为有明确的脑外伤史,并经头颅CT或MRI确诊;②年龄18~70岁,经头颅CT或MRI证实为局灶性脑损伤,病程≥1个月;③偏瘫侧下肢布氏分期≥III期,改良Ashworth量表≤2级,可独立步行10米,无共济失调等锥体外系症状;④无明显认知功能障碍,MMSE评分≥22分;⑤签署知情同意。 |
||||||||||||||||||||||
|
Inclusion criteria |
①The patients met the diagnostic criteria for ischemic or hemorrhagic stroke in "Diagnostic Points of Various Major Cerebrovascular Diseases in China 2019" or patients with a definite history of traumatic brain injury who were confirmed by head CT or MRI. ② The course of stroke was ≥1 month, the age was 18-70 years old, ③ Brunnstrom stage for the lower extremity was ≥III, and the modified Ashworth scale was ≤II. Patients can walk 10 meters independently, no ataxia and other extrapyramidal symptoms. ④No obvious cognitive function and speech impairment, MMSE score ≥22 points. ⑤ Sign informed consent. |
||||||||||||||||||||||
|
排除标准: |
①既往有卒中或脑外伤病史;既往或现阶段存在精神疾患及痴呆者;②合并恶性肿瘤、重症感染、严重心肺疾病等患者;③存在骨折、肢体严重畸形或关节挛缩者;④体内有金属异物或其它植入体内装置导致患者无法行核磁共振检查;⑤不愿配合,无法进行测试及评估者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
①Patients with previous history of stroke or traumatic brain injury, past or current mental disorders and cognitive impairment. ②Patients with malignant tumors, severe infections, serious cardiopulmonary diseases, etc. ③Patients with fractures, serious deformity of limbs or joint contracture. ④There are metal foreign bodies or other devices implanted in the body, which makes the patient unable to undergo magnetic resonance examination. ⑤Those who are unwilling to cooperate and unable to test and evaluate. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-01-01 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-06-01 00:00:00 至 To 2026-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
软件生成随机数字表;最小充分平衡随机化方法。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Software generated random number table; Minimum sufficient balance randomization method. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
数据采集过程中无法对医护人员评测者及研究参与者设盲,但数据分析过程采用单盲的设计方法,研究者不知情。 |
|
Blinding: |
During the data collection process, it is not possible to set blinds for medical staff evaluators and research participants, but the data analysis process adopts a single blind design method without the knowledge of the researchers. |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例报告表的保存:由研究者保管至临床试验结束后5年。 数据管理和数据可溯源性:本课题研究过程中对每个受试者进行编码并匿名化处理,研究过程中及研究结束后清晰、正确、完整、及时地收集受试者的基本资料、临床资料、检查及评定数据,并进行保密管理,保证数据可溯源。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Retention of case report forms: kept by the investigator until 5 years after the end of the clinical trial. Data management and data traceability: Each subject was coded and anonymized during the study, and basic data, clinical data, examination and assessment data of subjects were collected clearly, correctly, completely and timely during and after the study, and confidential management was carried out to ensure data traceability. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |